UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-42288

Cuprina Holdings (Cayman) Limited

(Registrant’s Name)

c/o Blk 1090 Lower Delta Road #06-08

Singapore 169201

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 18, 2025, Cuprina Holdings (Cayman) Limited (the “Company”) issued a press release announcing Cuprina forms Joint Venture Company with Aiodine Laboratory to Develop and Market Novel Iodine-based Solution as New Wound Care Therapy. This press release is furnished herewith as Exhibit 99.1.

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated November 18, 2025

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cuprina Holdings (Cayman) Limited

	By:	/s/ David Quek Yong Qi
	Name:	David Quek Yong Qi
	Title:	Chief Executive Officer and Director

Date: November 18, 2025

Cuprina Holdings (Cayman) LTD 6-K